☰

Ryan B. Rountree, Ph.D. - Publications

Affiliations: 
Stanford University, Palo Alto, CA 
Area:
molecular control and evolution of skeletal patterning
Tree Info Grants Similar researchers PubMed Report error

9/22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Blackburn J, Ohazama A, Kawasaki K, Otsuka-Tanaka Y, Liu B, Honda K, Rountree RB, Hu Y, Kawasaki M, Birchmeier W, Schmidt-Ullrich R, Kinoshita A, Schutte BC, Hammond NL, Dixon MJ, et al. The role of Irf6 in tooth epithelial invagination. Developmental Biology. 365: 61-70. PMID 22366192 DOI: 10.1016/J.Ydbio.2012.02.009  0.301
2010 Rountree RB, Willis CR, Dinh H, Blumberg H, Bailey K, Dean C, Peschon JJ, Holland PM. RIP4 regulates epidermal differentiation and cutaneous inflammation. The Journal of Investigative Dermatology. 130: 102-12. PMID 19626033 DOI: 10.1038/jid.2009.223  0.352
2009 Kahn J, Shwartz Y, Blitz E, Krief S, Sharir A, Breitel DA, Rattenbach R, Relaix F, Maire P, Rountree RB, Kingsley DM, Zelzer E. Muscle contraction is necessary to maintain joint progenitor cell fate. Developmental Cell. 16: 734-43. PMID 19460349 DOI: 10.1016/J.Devcel.2009.04.013  0.685
2008 Koyama E, Shibukawa Y, Nagayama M, Sugito H, Young B, Yuasa T, Okabe T, Ochiai T, Kamiya N, Rountree RB, Kingsley DM, Iwamoto M, Enomoto-Iwamoto M, Pacifici M. A distinct cohort of progenitor cells participates in synovial joint and articular cartilage formation during mouse limb skeletogenesis. Developmental Biology. 316: 62-73. PMID 18295755 DOI: 10.1016/J.Ydbio.2008.01.012  0.742
2007 Koyama E, Ochiai T, Rountree RB, Kingsley DM, Enomoto-Iwamoto M, Iwamoto M, Pacifici M. Synovial joint formation during mouse limb skeletogenesis: roles of Indian hedgehog signaling. Annals of the New York Academy of Sciences. 1116: 100-12. PMID 18083924 DOI: 10.1196/Annals.1402.063  0.758
2006 Gurley KA, Chen H, Guenther C, Nguyen ET, Rountree RB, Schoor M, Kingsley DM. Mineral formation in joints caused by complete or joint-specific loss of ANK function. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 21: 1238-47. PMID 16869722 DOI: 10.1359/Jbmr.060515  0.633
2004 Rountree RB, Schoor M, Chen H, Marks ME, Harley V, Mishina Y, Kingsley DM. BMP receptor signaling is required for postnatal maintenance of articular cartilage. Plos Biology. 2: e355. PMID 15492776 DOI: 10.1371/Journal.Pbio.0020355  0.722
2003 Settle SH, Rountree RB, Sinha A, Thacker A, Higgins K, Kingsley DM. Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse Gdf6 and Gdf5 genes. Developmental Biology. 254: 116-30. PMID 12606286 DOI: 10.1016/S0012-1606(02)00022-2  0.701
2001 Thut CJ, Rountree RB, Hwa M, Kingsley DM. A large-scale in situ screen provides molecular evidence for the induction of eye anterior segment structures by the developing lens. Developmental Biology. 231: 63-76. PMID 11180952 DOI: 10.1006/Dbio.2000.0140  0.576
Low-probability matches (unlikely to be authored by this person)
2019 Kelly A, Robbins DW, Tan M, Tenn-McClellan A, McIntosh J, Wu J, Konst Z, Kato D, Perez L, Tung J, Kolobova A, Ingallinera T, McKinnell J, Weiss D, Noviski M, ... ... Rountree R, et al. Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies Blood. 134: 3805-3805. DOI: 10.1182/blood-2019-129262  0.193
2016 Foy SP, Mandl SJ, Dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunology, Immunotherapy : Cii. PMID 26961085 DOI: 10.1007/S00262-016-1816-7  0.126
2024 Robbins DW, Noviski MA, Tan YS, Konst ZA, Kelly A, Auger P, Brathaban N, Cass R, Chan ML, Cherala G, Clifton MC, Gajewski S, Ingallinera TG, Karr D, Kato D, ... ... Rountree R, et al. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. Journal of Medicinal Chemistry. PMID 38300987 DOI: 10.1021/acs.jmedchem.3c01007  0.125
2016 Foy SP, Sennino B, Dela Cruz T, Cote JJ, Gordon EJ, Kemp F, Xavier V, Franzusoff A, Rountree RB, Mandl SJ. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. Plos One. 11: e0150084. PMID 26910562 DOI: 10.1371/Journal.Pone.0150084  0.071
2014 Mandl SJ, Rountree RB, Owen RB, dela Cruz T, Hwang O, Paranjpe G, Enstrom A, Franzusoff AJ, Goessl C, Breitmeyer JB. PROSTVAC, PSA-targeted immunotherapy: New evidence for mechanism of action. Journal of Clinical Oncology. 32: 3080-3080. DOI: 10.1200/jco.2014.32.15_suppl.3080  0.064
2012 Mandl SJ, Rountree RB, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Dirmeier U, Steigerwald R, Giffon T, Laus R, Delcayre A. Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunology, Immunotherapy : Cii. 61: 19-29. PMID 21822917 DOI: 10.1007/s00262-011-1077-4  0.061
2011 Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Brinkmann K, Dirmeier U, Laus R, Delcayre A. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Research. 71: 5235-44. PMID 21670078 DOI: 10.1158/0008-5472.CAN-10-4076  0.058
2015 Mandl SJ, Foy SP, Sennino B, dela Cruz T, Gordon E, Kemp F, Xavier V, Rountree RB, Franzusoff A. Anti-tumor efficacy and PD-L1 expression in the tumor microenvironment after poxvirus-based active immunotherapy and PD-1 blockade. Journal of Clinical Oncology. 33: 3079-3079. DOI: 10.1200/Jco.2015.33.15_Suppl.3079  0.046
2013 Foy SP, Rountree RB, Mandl SJ, Cote J, dela Cruz T, Gordon E, Trent E, Delcayre A. Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P72  0.029
2014 Mandl SJ, Rountree RB, Dela Cruz TB, Foy SP, Cote JJ, Gordon EJ, Trent E, Delcayre A, Franzusoff A. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. Journal For Immunotherapy of Cancer. 2: 34. PMID 25328681 DOI: 10.1186/s40425-014-0034-0  0.025
2014 Foy SP, Mandl SJ, dela Cruz T, Cote J, Gordon E, Trent E, Franzusoff AJ, Rountree RB. Magnitude and quality of tumor-infiltrating T-cell response upon poxvirus-based active immunotherapy alone and in combination with CTLA-4 immune checkpoint inhibition. Journal of Clinical Oncology. 32: 3013-3013. DOI: 10.1200/jco.2014.32.15_suppl.3013  0.021
2014 Foy SP, Rountree RB, Cote J, dela Cruz T, Gordon E, Trent E, Franzusoff A, Breitmeyer JB, Mandl SJ. Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer Journal For Immunotherapy of Cancer. 2: P124. DOI: 10.1186/2051-1426-2-S3-P124  0.016
2014 Foy SP, Rountree RB, Cote J, Gordon E, Trent E, Franzusoff AJ, Breitmeyer JB, Mandl SJ. Antitumor efficacy of poxvirus-based active immunotherapy alone and in combination with subtherapeutic dosing with immune checkpoint inhibitors. Journal of Clinical Oncology. 32: 3058-3058. DOI: 10.1200/jco.2014.32.15_suppl.3058  0.01
Hide low-probability matches.